Trimel Announces Change to Management Team

TORONTO--(BUSINESS WIRE)-- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced a change to its management team. Dr. Michael Bumby will be appointed Chief Financial Officer, succeeding Mr. Kenneth Howling, who will be leaving the Company to pursue other opportunities. Dr. Bumby will join Trimel as of August 3, 2015, however Mr. Howling will remain in his role until the end of August to ensure a smooth transition.

“The Board of Directors and I are delighted to welcome Dr. Bumby to the team,” said Tom Rossi, President and Chief Executive Officer of Trimel. “Dr. Bumby brings extensive pharmaceutical M&A experience to the table, as well as strong business and leadership skills that will prove invaluable as we execute on our growth strategy for the coming years.”

Mr. Rossi added, “I would also like to take this opportunity to thank Mr. Howling for the integral role he has played in the building of our Company and for his many contributions over the years. We wish him all the best in his future endeavours.”

Dr. Bumby joins Trimel from Antibe Therapeutics Inc., a publicly traded Canadian pharmaceutical company where he held the position of Chief Financial Officer since 2012. While at Antibe, he took the closely held, private company public via an initial public offering in June 2013.

He was previously Director, Corporate Finance & Investment Banking at Eli Lilly in the United States, where he led business development activities such as M&A and other transactions relating to both early and late stage assets. Some of his major accomplishments while in this role included leading the deal team in a +$260M acquisition of J&J’s Janssen Animal Health business, in addition to in-licensing a phase II oral JAK II inhibitor from Incyte Corporation and a post-phase III testosterone solution (Axiron®) from Acrux Ltd.

From 2006 to 2009, Dr. Bumby served as the CFO of a subsidiary of Eli Lilly in Prague, Czech Republic. Prior to this role, he served increasingly senior financial roles at Eli Lilly global headquarters and in Canada beginning in 1998. Before embarking on a career in pharmaceuticals, Dr. Bumby was an equine and small animal veterinarian. He holds a Doctor of Veterinary Medicine from the University of Guelph and an MBA from the University of Toronto.

About Trimel

Trimel is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.

Trimel markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing Trimel's licensed nasal gel technology, is the first and only testosterone nasal gel approved and launched in the United States for replacement therapy in adult males diagnosed with hypogonadism, and is currently filed for approval in Canada. The commercial rights to NATESTO™ in the United States and Mexico have been licensed by Trimel to an affiliate of Endo International plc. TEFINA™, a “use as required” nasal testosterone gel, is Trimel’s drug development candidate aimed at addressing a significant unmet need for women with female orgasmic disorder.

For more information, please visit www.trimelpharmaceuticals.com.

Notice regarding forward-looking statements:

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2015 which is available at Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150713005433/en/

Trimel Pharmaceuticals
Tiana DiMichele, 416-679-0822
[email protected]

Source: Trimel

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Thunder Bridge Capital Partners V prices $261M IPO on Nasdaq
• Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
• Londian Wason New Energy Tech opens at $26, above IPO price of $22